Share on StockTwits

Cardinal Health (NYSE:CAH) CEO Michael C. Kaufmann sold 6,833 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $72.06, for a total value of $492,385.98. Following the completion of the sale, the chief executive officer now directly owns 118,576 shares in the company, valued at approximately $8,544,587. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Cardinal Health (NYSE:CAH) traded up 1.19% on Thursday, hitting $73.34. The stock had a trading volume of 880,880 shares. Cardinal Health has a 52 week low of $49.65 and a 52 week high of $74.40. The stock’s 50-day moving average is $71.18 and its 200-day moving average is $69.61. The company has a market cap of $24.690 billion and a price-to-earnings ratio of 21.45.

Cardinal Health (NYSE:CAH) last announced its earnings results on Monday, August 4th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.02. The company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $21.88 billion. During the same quarter in the previous year, the company posted $0.79 earnings per share. The company’s revenue for the quarter was down 9.9% on a year-over-year basis. On average, analysts predict that Cardinal Health will post $4.25 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be given a dividend of $0.3425 per share. This represents a $1.37 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date of this dividend is Monday, September 29th.

A number of analysts have recently weighed in on CAH shares. Analysts at Argus reiterated a “buy” rating on shares of Cardinal Health in a research note on Monday. They now have a $71.43 price target on the stock, down previously from $83.00. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $82.00 price target on the stock, up previously from $77.00. Finally, analysts at Credit Suisse reiterated an “outperform” rating on shares of Cardinal Health in a research note on Tuesday, August 5th. They now have a $80.00 price target on the stock, up previously from $76.00. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $77.93.

Cardinal Health, Inc is a healthcare services company providing pharmaceutical and medical products and services to pharmacies, hospitals, ambulatory surgery centers, clinical laboratories, physician offices and other healthcare providers.

Receive News & Ratings for Cardinal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.